FDA Approves SPIRONOLACTONE — NorthStar Rx LLC
NorthStar Rx LLC announced on Friday that its ANDA approval of the oral generic version of SPIRONOLACTONE has been granted by the FDA, marking a new entry for the existing heart failure product. This recent clarification of the November 2014 approval is likely to enhance NorthStar’s portfolio further competing in the generic market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed